tetano
Editor, Senior Moderator
Virol J
. 2025 Jul 23;22(1):252.
doi: 10.1186/s12985-025-02886-5. Extracellular DNA, hyaluronic acid, HIF pathways, and LncRNAs as predictive biomarkers of severe COVID-19
Evgen Dubrovskyi[SUP] 1 [/SUP], Tetiana Drevytska[SUP] 1 [/SUP], Alla Portnychenko[SUP] 1 [/SUP], Victor Dosenko[SUP] 1 [/SUP], Iryna Halabitska[SUP] 2 [/SUP], Pavlo Petakh[SUP] 3 [/SUP], Denis E Kainov[SUP] 4 [/SUP], Oleksandr Kamyshnyi[SUP] 5 [/SUP]
Affiliations
The clinical course of COVID-19 ranges from mild symptoms to severe complications, and common laboratory markers such as D-dimer, ferritin, interleukin-6 (IL-6), and C-reactive protein (CRP) often do not accurately predict which patients will develop severe disease. In this study, we reviewed current literature and analyzed additional data to assess emerging biomarkers that may help identify high-risk cases earlier. These include circulating cell-free DNA (cfDNA) produced during neutrophil extracellular trap formation (NETosis), hyaluronic acid (HA), hypoxia-inducible factor (HIF) isoforms, and related long non-coding RNAs such as HAS2-AS1 and HIF1-AS1. Increased levels of cfDNA/NETs, HA, and elevated expression of HIF isoforms and their lncRNAs are closely associated with key features of severe COVID-19, including immune-related blood clotting, low oxygen levels, vascular damage, and chronic inflammation. These biomarkers show promise for use in risk assessment tools that could support earlier clinical decisions and improve outcomes in patients with COVID-19.
Keywords: Biomarkers; COVID-19; Extracellular DNA (cfDNA); Hyaluronic acid (HA); Hypoxia-inducible factors (HIF-1α, HIF-2α, HIF-3α); Immunothrombosis; Inflammation; Long non-coding RNAs (HAS2-AS1, HIF1-AS1); NETosis; SARS-CoV-2.
. 2025 Jul 23;22(1):252.
doi: 10.1186/s12985-025-02886-5. Extracellular DNA, hyaluronic acid, HIF pathways, and LncRNAs as predictive biomarkers of severe COVID-19
Evgen Dubrovskyi[SUP] 1 [/SUP], Tetiana Drevytska[SUP] 1 [/SUP], Alla Portnychenko[SUP] 1 [/SUP], Victor Dosenko[SUP] 1 [/SUP], Iryna Halabitska[SUP] 2 [/SUP], Pavlo Petakh[SUP] 3 [/SUP], Denis E Kainov[SUP] 4 [/SUP], Oleksandr Kamyshnyi[SUP] 5 [/SUP]
Affiliations
- PMID: 40702494
- DOI: 10.1186/s12985-025-02886-5
The clinical course of COVID-19 ranges from mild symptoms to severe complications, and common laboratory markers such as D-dimer, ferritin, interleukin-6 (IL-6), and C-reactive protein (CRP) often do not accurately predict which patients will develop severe disease. In this study, we reviewed current literature and analyzed additional data to assess emerging biomarkers that may help identify high-risk cases earlier. These include circulating cell-free DNA (cfDNA) produced during neutrophil extracellular trap formation (NETosis), hyaluronic acid (HA), hypoxia-inducible factor (HIF) isoforms, and related long non-coding RNAs such as HAS2-AS1 and HIF1-AS1. Increased levels of cfDNA/NETs, HA, and elevated expression of HIF isoforms and their lncRNAs are closely associated with key features of severe COVID-19, including immune-related blood clotting, low oxygen levels, vascular damage, and chronic inflammation. These biomarkers show promise for use in risk assessment tools that could support earlier clinical decisions and improve outcomes in patients with COVID-19.
Keywords: Biomarkers; COVID-19; Extracellular DNA (cfDNA); Hyaluronic acid (HA); Hypoxia-inducible factors (HIF-1α, HIF-2α, HIF-3α); Immunothrombosis; Inflammation; Long non-coding RNAs (HAS2-AS1, HIF1-AS1); NETosis; SARS-CoV-2.